TreQ Unveils Compass SG25B: The Open-Architecture Quantum Innovation Station
ANAHEIM, CA, UNITED STATES, March 17, 2025 / EINPresswire.com / -- TreQ, the quantum systems engineering and manufacturing company, today announces the launch of the Compass SG25B to break down the barriers to quantum innovation. A turnkey, open-architecture quantum computing system, Compass SG25B is designed for researchers and developers eager to move their work forward without the bottlenecks of infrastructure logistics.
Built with extensibility, upgradability, and low-level access in mind, Compass SG25B enables quantum pioneers to push the boundaries of discovery, while leveraging the expertise of industry-leading quantum technology providers including Rigetti Computing, Qblox, QuantrolOx, and Bluefors.
'Quantum computing development shouldn't be held back by supply chain challenges or closed architectures,' said Mandy Birch, CEO, TreQ. 'Compass SG25B is an innovation station built for explorers. The open-architecture system frees researchers to focus on breakthroughs instead of lab infrastructure. With this launch, we're not just delivering hardware; we're delivering momentum.'
Built from an Emerging Quantum Supply Chain
TreQ's Compass SG25B is the result of innovations across the quantum ecosystem:
- Rigetti Computing provides the Novera™ 9-qubit processor, built with the same Ankaa™-class architecture powering its larger-scale quantum systems.
- Qblox delivers a modular control stack, designed to grow with evolving quantum research needs.
- QuantrolOx provides Quantum EDGE, an advanced qubit automation platform streamlining tuning and calibration.
- Bluefors contributes its Ultra-Compact LD dilution refrigerator, ensuring seamless integration of cooling and cryogenic control in a space-efficient design.
During a successful integration and test demonstration in February, the system met its target performance specifications. Today, the Compass SG25B is available for worldwide deployment, providing researchers with a fully realized, turnkey, open-architecture quantum computing system.
TreQ's supply chain partners emphasize the strategic importance of open, accessible quantum systems:
'Open architecture unlocks innovative and creative solutions to the challenges posed by the transformative power of quantum computing. Rigetti's Novera QPU brings high-fidelity quantum operations to Compass SG25B, enabling researchers to explore and innovate with confidence.'
— Dr. Subodh Kulkarni, CEO, Rigetti
'The flexibility of open architecture is essential for establishing the breakthroughs required towards industrial-scale quantum computers. Qblox Cluster is the platform to bring out the best in SG25B in terms of speed to results, optimal fidelity and is ready to scale with the needs of its users.'
— Niels Bultink, CEO, Qblox
'With QuantrolOx Quantum EDGE, researchers can automate and optimize their quantum experiments, accelerating time to results.'
— Vishal Chatrath, CEO, QuantrolOx
'The Bluefors Ultra-Compact LD is engineered for efficiency and integration, making Compass SG25B a smart choice for labs that need seamless, high-performance cooling.'
—Mikko Nurminen, CSO, Bluefors
Infrastructure to Bring Research to the Forefront
Compass SG25B is upgradeable and engineered for flexibility, ensuring institutions and enterprises can stay ahead with capital efficiency in the rapidly evolving quantum landscape.
TreQ is currently accepting bids for 2025 and 2026 reference sites. To be among the first to host an open-architecture quantum system, visit treq.tech/event/20250317pr or contact Gibson Armstrong at [email protected].
About TreQ
TreQ is a global quantum systems engineering and manufacturing company building and operating bespoke, open-architecture quantum computing clusters.
Josie Fellows
TFD - Think Feel Do
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998
Yahoo
7 hours ago
- Yahoo
Should You Buy the Post-Earnings Dip in Rigetti Computing Stock?
Rigetti Computing (RGTI) says its net loss more than tripled on a year-over-year basis to roughly $40 million in the second quarter. Shares of the quantum-tech specialist tanked nearly 8% on Friday also because its revenue came in down over 40% on a year-over-year basis as well. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Rigetti Computing stock has been a lucrative investment over the past four months. Despite the recent plunge, it's up more than 100% versus its April low. Should You Avoid Buying RGTI Stock on the Post-Earnings Decline? According to Subodh Kulkarni, the chief executive of Rigetti Computing, quantum technology could evolve into a trillion-dollar-per-year market in the long term. In the next four to five years, however, 'our view is still very much in the R&D stage,' he told Barron's in a recent interview. Kulkarni's remarks make RGTI shares materially less attractive to own especially when they're up well over 150% versus their year-to-date low despite revenue decelerating at an alarming rate. Rigetti Computing Shares Are Egregiously Overvalued Rigetti Computing raised some $350 million via a stock offering in its second financial quarter, effectively wiping its balance sheet of all debt. But it's hardly a positive for the Nasdaq-listed firm since the offering nearly doubled the number of its shares outstanding, raising dilution risks. More importantly, Rigetti Computing is trading at a price-sales (P/S) ratio of more than 480x at writing, which indicates gross overvaluation. Investors should also note that RGTI has not yet achieved quantum supremacy, which theoretically makes peer D-Wave (QBTS) a better investment than Rigetti Computing stock for exposure to quantum technology. How Wall Street Recommends Playing Rigetti Computing Investors should also note that Wall Street no longer sees meaningful further upside in RGTI shares from current levels. While the consensus rating on Rigetti Computing stock remains at 'Strong Buy,' the mean target of roughly $17.80 indicates potential for only about 6.7% upside. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
